iMMagine-4: Anitocabtagene Autoleucel vs Standard of Care in Newly Diagnosed Multiple Myeloma

Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Arm A: Standard of Care Therapy (SOCT) with Arm B: Anitocabtagene Autoleucel (2 arms). Primary endpoints: Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 months and Progression-Free Survival up to 15 years. Planned start Jan 2027; status: not yet recruiting.